# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-270230
Filing Date
2025-11-07
Accepted
2025-11-06 17:58:42
Documents
68
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | nktr-20250930.htm iXBRL | 10-Q | 2830318
2 | EX-31.1 | nktr-ex31_1.htm | EX-31.1 | 15054
3 | EX-31.2 | nktr-ex31_2.htm | EX-31.2 | 15282
4 | EX-32.1 | nktr-ex32_1.htm | EX-32.1 | 11091
| Complete submission text file | 0001193125-25-270230.txt |  | 10000789

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | nktr-20250930.xsd | EX-101.SCH | 1223122
71 | EXTRACTED XBRL INSTANCE DOCUMENT | nktr-20250930_htm.xml | XML | 1797007

Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-24006 | Film No.: 251459850
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)